FASL-844 T/C polymorphism: A biomarker of good prognosis of breast cancer in the Tunisian population

Wijden Mahfoudh, Noureddine Bouaouina, Sallouha Gabbouj, Lotfi Chouchane

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The single nucleotide polymorphism, rs763110 (-844 T/C) of the FASL gene, is located within a putative binding motif of CAAT/enhancer-binding protein β transcription factor. Higher basal expression of FASL is significantly associated with the FASL-844 C allele compared with the FASL-844 T allele suggesting that the FASL-844 T/C polymorphism may influence FASL expression and FASL-mediated signalling, and ultimately, the susceptibility to cancer. Therefore, we carried out a population-based study to estimate the FASL-844 C allele frequency in our population and to investigate, in a case-control study, the potential association of the FASL-844 T/C polymorphism with the risk and prognosis of breast cancer in Tunisia.FASL-844 T/C polymorphism was examined in a Tunisian population-based case-control of 438 patients with breast cancer and 332 control subjects using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. By using TT genotype as reference, no significant association was found between any genotype and the risk of developing breast cancer. The frequency of the FASL-844 C allele was 46.3% among the cases and 43.7% among the controls. Similarly, by using T allele as reference, this difference was also not statistically significant. We observed FASL-844 CC genotype and FASL-844 C allele were significantly associated with SBR 1-2 tumour grade (OR=0.42, P=0.007; OR=0.65, P=0.005, respectively). In patients with diagnosis age 50years, FASL-844 CC genotype and C allele showed significant associations with T1-T2 clinical tumour size (OR=0.34, P=0.01; OR=0.65, P=0.02, respectively) and SBR grade 1-2 (OR=0.41, P=0.02; OR=0.62, P=0.01, respectively). A marginally significant association was also found with negative nodal status (OR=0.53, P=0.06; OR=0.73, P=0.07, respectively). Thus, the FASL-844 CC genotype and C allele seem to be associated with a good prognosis in patients with diagnosis age 50years.

Original languageEnglish
Pages (from-to)932-938
Number of pages7
JournalHuman Immunology
Volume73
Issue number9
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Biomarkers
Alleles
Breast Neoplasms
Genotype
Population
CCAAT-Enhancer-Binding Proteins
Neoplasms
Tunisia
Gene Frequency
Restriction Fragment Length Polymorphisms
Single Nucleotide Polymorphism
Case-Control Studies
Transcription Factors
Polymerase Chain Reaction
Genes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

FASL-844 T/C polymorphism : A biomarker of good prognosis of breast cancer in the Tunisian population. / Mahfoudh, Wijden; Bouaouina, Noureddine; Gabbouj, Sallouha; Chouchane, Lotfi.

In: Human Immunology, Vol. 73, No. 9, 09.2012, p. 932-938.

Research output: Contribution to journalArticle

Mahfoudh, Wijden ; Bouaouina, Noureddine ; Gabbouj, Sallouha ; Chouchane, Lotfi. / FASL-844 T/C polymorphism : A biomarker of good prognosis of breast cancer in the Tunisian population. In: Human Immunology. 2012 ; Vol. 73, No. 9. pp. 932-938.
@article{763d43d13f3a4e288b5881f2fd8fb631,
title = "FASL-844 T/C polymorphism: A biomarker of good prognosis of breast cancer in the Tunisian population",
abstract = "The single nucleotide polymorphism, rs763110 (-844 T/C) of the FASL gene, is located within a putative binding motif of CAAT/enhancer-binding protein β transcription factor. Higher basal expression of FASL is significantly associated with the FASL-844 C allele compared with the FASL-844 T allele suggesting that the FASL-844 T/C polymorphism may influence FASL expression and FASL-mediated signalling, and ultimately, the susceptibility to cancer. Therefore, we carried out a population-based study to estimate the FASL-844 C allele frequency in our population and to investigate, in a case-control study, the potential association of the FASL-844 T/C polymorphism with the risk and prognosis of breast cancer in Tunisia.FASL-844 T/C polymorphism was examined in a Tunisian population-based case-control of 438 patients with breast cancer and 332 control subjects using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. By using TT genotype as reference, no significant association was found between any genotype and the risk of developing breast cancer. The frequency of the FASL-844 C allele was 46.3{\%} among the cases and 43.7{\%} among the controls. Similarly, by using T allele as reference, this difference was also not statistically significant. We observed FASL-844 CC genotype and FASL-844 C allele were significantly associated with SBR 1-2 tumour grade (OR=0.42, P=0.007; OR=0.65, P=0.005, respectively). In patients with diagnosis age 50years, FASL-844 CC genotype and C allele showed significant associations with T1-T2 clinical tumour size (OR=0.34, P=0.01; OR=0.65, P=0.02, respectively) and SBR grade 1-2 (OR=0.41, P=0.02; OR=0.62, P=0.01, respectively). A marginally significant association was also found with negative nodal status (OR=0.53, P=0.06; OR=0.73, P=0.07, respectively). Thus, the FASL-844 CC genotype and C allele seem to be associated with a good prognosis in patients with diagnosis age 50years.",
author = "Wijden Mahfoudh and Noureddine Bouaouina and Sallouha Gabbouj and Lotfi Chouchane",
year = "2012",
month = "9",
doi = "10.1016/j.humimm.2012.06.001",
language = "English",
volume = "73",
pages = "932--938",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - FASL-844 T/C polymorphism

T2 - A biomarker of good prognosis of breast cancer in the Tunisian population

AU - Mahfoudh, Wijden

AU - Bouaouina, Noureddine

AU - Gabbouj, Sallouha

AU - Chouchane, Lotfi

PY - 2012/9

Y1 - 2012/9

N2 - The single nucleotide polymorphism, rs763110 (-844 T/C) of the FASL gene, is located within a putative binding motif of CAAT/enhancer-binding protein β transcription factor. Higher basal expression of FASL is significantly associated with the FASL-844 C allele compared with the FASL-844 T allele suggesting that the FASL-844 T/C polymorphism may influence FASL expression and FASL-mediated signalling, and ultimately, the susceptibility to cancer. Therefore, we carried out a population-based study to estimate the FASL-844 C allele frequency in our population and to investigate, in a case-control study, the potential association of the FASL-844 T/C polymorphism with the risk and prognosis of breast cancer in Tunisia.FASL-844 T/C polymorphism was examined in a Tunisian population-based case-control of 438 patients with breast cancer and 332 control subjects using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. By using TT genotype as reference, no significant association was found between any genotype and the risk of developing breast cancer. The frequency of the FASL-844 C allele was 46.3% among the cases and 43.7% among the controls. Similarly, by using T allele as reference, this difference was also not statistically significant. We observed FASL-844 CC genotype and FASL-844 C allele were significantly associated with SBR 1-2 tumour grade (OR=0.42, P=0.007; OR=0.65, P=0.005, respectively). In patients with diagnosis age 50years, FASL-844 CC genotype and C allele showed significant associations with T1-T2 clinical tumour size (OR=0.34, P=0.01; OR=0.65, P=0.02, respectively) and SBR grade 1-2 (OR=0.41, P=0.02; OR=0.62, P=0.01, respectively). A marginally significant association was also found with negative nodal status (OR=0.53, P=0.06; OR=0.73, P=0.07, respectively). Thus, the FASL-844 CC genotype and C allele seem to be associated with a good prognosis in patients with diagnosis age 50years.

AB - The single nucleotide polymorphism, rs763110 (-844 T/C) of the FASL gene, is located within a putative binding motif of CAAT/enhancer-binding protein β transcription factor. Higher basal expression of FASL is significantly associated with the FASL-844 C allele compared with the FASL-844 T allele suggesting that the FASL-844 T/C polymorphism may influence FASL expression and FASL-mediated signalling, and ultimately, the susceptibility to cancer. Therefore, we carried out a population-based study to estimate the FASL-844 C allele frequency in our population and to investigate, in a case-control study, the potential association of the FASL-844 T/C polymorphism with the risk and prognosis of breast cancer in Tunisia.FASL-844 T/C polymorphism was examined in a Tunisian population-based case-control of 438 patients with breast cancer and 332 control subjects using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. By using TT genotype as reference, no significant association was found between any genotype and the risk of developing breast cancer. The frequency of the FASL-844 C allele was 46.3% among the cases and 43.7% among the controls. Similarly, by using T allele as reference, this difference was also not statistically significant. We observed FASL-844 CC genotype and FASL-844 C allele were significantly associated with SBR 1-2 tumour grade (OR=0.42, P=0.007; OR=0.65, P=0.005, respectively). In patients with diagnosis age 50years, FASL-844 CC genotype and C allele showed significant associations with T1-T2 clinical tumour size (OR=0.34, P=0.01; OR=0.65, P=0.02, respectively) and SBR grade 1-2 (OR=0.41, P=0.02; OR=0.62, P=0.01, respectively). A marginally significant association was also found with negative nodal status (OR=0.53, P=0.06; OR=0.73, P=0.07, respectively). Thus, the FASL-844 CC genotype and C allele seem to be associated with a good prognosis in patients with diagnosis age 50years.

UR - http://www.scopus.com/inward/record.url?scp=84865377829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865377829&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2012.06.001

DO - 10.1016/j.humimm.2012.06.001

M3 - Article

C2 - 22732091

AN - SCOPUS:84865377829

VL - 73

SP - 932

EP - 938

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 9

ER -